Guggenheim lowered the firm’s price target on Krystal Biotech (KRYS) to $189 from $195 and keeps a Buy rating on the shares. $88M in Vyjuvek sales “handily missed” the $96.8M consensus and without a clear outlook on new patient adds and compliance, the next couple of quarters are “challenging” until the company gets traction in the EU and Japan, the analyst tells investors in a post-earnings note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech: Buy Rating Amid Temporary Revenue Dip and Promising Growth Prospects
- Krystal Biotech Reports Strong Q1 2025 Results
- Krystal Biotech’s Earnings Call Highlights Growth and Expansion
- Krystal Biotech’s Growth Potential: Addressing Challenges with Strategic Initiatives and Strong Market Presence
- Krystal Biotech’s Long-Term Growth Potential Amid Short-Term Challenges: A Buy Rating by Sami Corwin
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue